What the FDA labels say about taking them together
Axitinib and etravirine
Axitinib's FDA label of March 12, 2026 names etravirine in its drug interactions section; the etravirine label PlainMeds reads does not name axitinib. The axitinib label: “Moderate CYP3A4/5 inducers may also reduce the plasma exposure of axitinib and should be avoided if possible.”
Check it at the source: the axitinib FDA label on DailyMed (effective March 12, 2026, U.S. Pharmaceuticals); the etravirine FDA label on DailyMed (effective August 15, 2023, Janssen Products LP).
What does the axitinib label say about etravirine?
Axitinib label, drug interactionsModerate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of axitinib and should be avoided if possible.
Source: FDA drug label (INLYTA), NDA202324 (Pf Prism Cv), as published by U.S. Pharmaceuticals, effective March 12, 2026 (SPL set 8a903e31-936e-4ed7-8a59-59f32374f338), via openFDA; the full label on DailyMed
What does the etravirine label say about axitinib?
Etravirine's label (effective August 15, 2023) does not name axitinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Intelence), Janssen Products LP, effective August 15, 2023 (SPL set 6a9cbc29-9f15-4b24-8d86-206b82887f3d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Axitinib | Etravirine | |
|---|---|---|
| Labeled for | n/a | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $9.94 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once